Melody Mendenhall DNP, ANP-C

Dynamic Nurse Practitioner with extensive oncology expertise at UCLA Health, excelling in patient assessment and education. Proven track record in clinical research and quality improvement initiatives, enhancing patient outcomes through interdisciplinary collaboration. Adept at mentoring junior staff and implementing tailored treatment plans, fostering a culture of excellence in patient care.

• NP-C, American Association of Nurse Practitioners, 02/11/24
• BLS, American Heart Association, 01/29/23
• California, Registered Nurse, RN622889, 01/31/25
• California, Nurse Practitioner, NP16776, 01/31/25
• DEA, MM1679298, 01/31/26

• Oncology Clinical Nursing Review Course, Care for The Lung Cancer Patient, Lecturer, 2013 - Present
• Treatment Options in Lung Cancer, Merck, Lecturer, 2015 - Present

• Artificial Intelligence patient education, 2024 - 2026, Created oncology education program using Artificial Intelligence. Published abstract on AI vs human produced education (2025). Collected data on patient attitudes around AI (publication pending). Generated AI-assisted patient education materials.
• Clinical Research Sub-Investigator Training, 2025 - 2026, Created a committee on sub-investigator training for clinical research. With committee support, created a sub-investigator onboarding program.
• Oncology immediate-care program, 2025 - 2026, Assisted in creating and implementing an oncology immediate care program. Implementation March 2026.

PUBLICATIONS

Research Papers - Peer Reviewed

• Goldman, J. W., Abdalla, B., Mendenhall, M. A., Sisk, A., Hunt, J., Danovitch, G. M., & Lum, E. L. (2018). PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report. BMC Nephrology, 19(1), 210.
• Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., … Garon, E. B. (2018). A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. Journal of Thoracic Oncology : Official publication of the International Association for the Study of Lung Cancer, 13(8), 1138–1145.
• Shen, J., Chang, J., Mendenhall, M., Cherry, G., Goldman, J. W., & Kulkarni, R. P. (2018). Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Therapeutic Advances in Medical Oncology, 10
• Lisberg, A., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A., Morris, K., Linares, P., Adame, C., Spiegel, M. L., Wells, C., McKenzie, J., Ledezma, B., Mendenhall, M., Abarca, P., Bornazyan, K., Hunt, J., Moghadam, N., Chong, N., Nameth, D., … Garon, E. B. (2018). Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunology Research, 6(3), 288–294
• Spiegel, M. L., Goldman, J. W., Wolf, B. R., Nameth, D. J., Grogan, T. R., Lisberg, A. E., Wong, D. J. L., Ledezma, B. A., Mendenhall, M. A., Genshaft, S. J., Gutierrez, A. J., Abtin, F., Wallace, W. D., Adame, C. R., McKenzie, J. R., Abarca, P. A., Li, A. J., Strunck, J. L., Famenini, S., Carroll, J. M., … Garon, E. B. (2017). Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer, 123(24), 4800–4807.
• Goldman, J. W., Mendenhall, M. A., & Rettinger, S. R. (2016). Hyperglycemia associated with targeted oncologic treatment: Mechanisms and management. The Oncologist, 21(11), 1326–1336.
• Sequist, L. V., Soria, J. C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., Aisner, D. L., Doebele, R. C., Galasso, C., Garon, E. B., Heist, R. S., Logan, J., Neal, J. W., Mendenhall, M. A., Nichols, S., Piotrowska, Z., … Camidge, D. R. (2015). Rociletinib in EGFR-mutated non-small-cell lung cancer. The New England Journal of Medicine, 372(18), 1700–1709.
• Mendenhall, M. A., & Goldman, J. W. (2015). MET-mutated NSCLC with major response to crizotinib. Journal of Thoracic Oncology : Official publication of the International Association for the Study of Lung Cancer, 10(5), e33–e34.

ABSTRACTS

• Gavin Hui, ….Mendenhall, M.A. et al (2024). Artificial intelligence vs. physicians: Quality of oncology patient education materials.. JCO Oncol Pract 20, 408-408(2024).
• Jonathan W. Goldman…Mendenhall, M.A, et al. (2023). UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.. JCO 41, e21165-e21165.
• Goldman, J.W…Mendenhall, M.A. et al (2022). Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).. JCO 40, 8517-8517.
• Mulroy, M…Mendenhall, M.A. et al. (2021). Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).. JCO 39, 8564-8564.
• Cummings, A…, Mendenhall, M.A. et al. (2019). Phase 2 Study of Talazoparib .Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, Volume 14, Issue 10, S815 - S816

CHAPTERS

• Lung Cancer Chapter, in Oncology Nursing Certification Review, Oncology Nursing Society (2023)

POSTERS

• Mendenhall, M., Velez, M., Goldman, J. (2017, February 22-25). Combination rociletinib and atezolizumab therapy for NSCLC: Review of three patients [Poster presentation]. IASLC: Targeted Therapies of Lung Cancer Meeting [Santa Monica, CA].

DISSERTATION

The Utility and Feasibility of an App-Based Mindfulness Intervention in   Patients With Metastatic Non-Small-Cell Lung Cancer Experiencing   Symptoms of Anxiety and Depression (DNP Scholarly Project)

Chair: Dr. Su Yong Jung

Committee Members:  Dr. Jonathan Goldman, Dr Betty Chang, Dr.   Benissa Salem

• UCLA School of Nursing, Clinical Preceptor, 2013 - Present
• Hong Kong Oncology Nursing Education Series (Lung Cancer) March 2026

• UCLA Hematology/Oncology, Founding Member, Patient Education Committee, 2022 - Present
• California Association of Nurse Practitioners, Health Policy Committee, 01/01/24 - 01/01/25
• UCLA, Member, Immunotherapy Toxicity Committee, 01/01/24 - Present
• California Nurses Association, Chair, Medicare for All Statewide Committee, 02/01/24 - Present
• UCLA, Board Member, Advanced Practice Provider Council, 07/01/24 - Present
• UCLA Nursing Executive Council, APP Council representative, 09/01/24 - 04/01/25
• Doctoral Alumni Council UCLA, 2024-present
• California Nursing Association, Union Representative for Ambulatory Hematology/Oncology, 05/01/23 - 5/2025

• Rae Huang for Mayor Campaign Volunteer, 2/2026-present
• Los Angeles Community Action Committee Member 1/2026- Present
• National Healthcare Lobby Day, Nurse Lobbyist, 2024
• American Acadamy of Colleges of Nursing Student Policy Summit, DNP representative, March 2024
• Medicare for All Campaign, National Nurses United, 2/2023- Present
• California Lobby Day, Nurse Lobbyist 2022, 2023